Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03665129
Recruitment Status : Recruiting
First Posted : September 11, 2018
Last Update Posted : February 12, 2019
Sponsor:
Collaborator:
MedImmune LLC
Information provided by (Responsible Party):
Innate Pharma

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021